About the Journal
Immunotherapy is a treatment procedure which enhances or supress the body’s immune system to fight against a disease. Immunotherapies which enhance the immune response are called as activation immunotherapies and those which reduce or suppress the immune response are called as suppression immunotherapies. Immunotherapy is of many types but the major immunotherapies for cancer include Monoclonal antibodies, Cancer vaccines and Non-specific immunotherapies.
The Journal of immunotherapy covers a wide range of topics related to allergy immunotherapy, cancer immunotherapy, immunotherapy for Kidney failure, lung cancer immunotherapy, melanoma immunotherapy, prostate cancer immunotherapy, sublingual immunotherapy, immunotherapy for HIV, immunotherapy for autoimmune diseases and transplantation, biomarkers for cancer immunotherapy, drug delivery systems and drug interactions, novel immunotherapeutic agents and immunotherapeutics clinical trials for immunotherapy etc. The journal also covers immunotherapeutic products, regulatory and FDI guidelines for immunotherapeutics and immunotherapy for kidney failure.
The journal of immunotherapy accepts all types of articles including research, review, case reports, commentaries, hypotheses, meeting reports, editorials and short reports.
Journal of immunotherapy is using Editorial Tracking System for quality in review process. It is an online manuscript submission, review and tracking system used by most of the best open access journals. Review processing is performed by the editorial board members of Journal or outside experts; at least two independent reviewers approval followed by editor's approval is required for acceptance of any citable manuscript.
Longdom Publishing SL organizes 1000+ conferences every year across USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members. Authors are requested to submit manuscript on Editorial Tracking, [email protected]